Thursday, September 29, 2022 10:52:12 AM
Recent ATXI News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 12:30:20 PM
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) • GlobeNewswire Inc. • 05/16/2024 12:30:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:01:25 PM
- Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/13/2024 04:15:21 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/10/2024 08:53:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/10/2024 08:52:35 PM
- Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds • GlobeNewswire Inc. • 04/29/2024 12:00:14 PM
- Avenue Therapeutics Announces Reverse Stock Split • GlobeNewswire Inc. • 04/24/2024 11:30:41 AM
- Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024 • GlobeNewswire Inc. • 03/25/2024 12:30:00 PM
- Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights • GlobeNewswire Inc. • 03/18/2024 08:05:14 PM
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq • GlobeNewswire Inc. • 03/15/2024 12:15:01 PM
- Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting • GlobeNewswire Inc. • 03/11/2024 12:00:17 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/08/2024 09:31:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 09:15:48 PM
- Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy • GlobeNewswire Inc. • 02/22/2024 01:30:08 PM
- Form DEF 14C - Other definitive information statements • Edgar (US Regulatory) • 01/29/2024 01:00:27 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 01/24/2024 09:11:38 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 01/17/2024 10:05:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 11:01:38 AM
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference • GlobeNewswire Inc. • 01/11/2024 01:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 10:28:40 PM
- Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds • GlobeNewswire Inc. • 01/05/2024 02:15:43 PM
- Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol • GlobeNewswire Inc. • 01/04/2024 01:30:44 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM